Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]
SEC Accession No. 0001641172-25-023566
Filing Date
2025-08-13
Accepted
2025-08-13 17:01:00
Documents
68
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q/A form10-qa.htm   iXBRL 10-Q/A 845214
2 EX-31.1 ex31-1.htm EX-31.1 18755
3 EX-31.2 ex31-2.htm EX-31.2 18692
4 EX-32.1 ex32-1.htm EX-32.1 8962
5 EX-32.2 ex32-2.htm EX-32.2 8795
  Complete submission text file 0001641172-25-023566.txt   4807159

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE asbp-20250331.xsd EX-101.SCH 47310
7 XBRL CALCULATION FILE asbp-20250331_cal.xml EX-101.CAL 40845
8 XBRL DEFINITION FILE asbp-20250331_def.xml EX-101.DEF 205405
9 XBRL LABEL FILE asbp-20250331_lab.xml EX-101.LAB 319451
10 XBRL PRESENTATION FILE asbp-20250331_pre.xml EX-101.PRE 267047
70 EXTRACTED XBRL INSTANCE DOCUMENT form10-qa_htm.xml XML 584770
Mailing Address 23150 FASHION DRIVE, SUITE 232 ESTERO FL 33928
Business Address 23150 FASHION DRIVE, SUITE 232 ESTERO FL 33928 561-704-8527
Aspire Biopharma Holdings, Inc. (Filer) CIK: 0001847345 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 10-Q/A | Act: 34 | File No.: 001-41293 | Film No.: 251212656
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)